Lisa Schaeffer, Nesrine Ben-Anaya, Christina Sorbe, Stephan Jeff Rustenbach, Ulrich Mrowietz, Matthias Augustin
{"title":"布达鲁单抗的实际疗效和药物存活率：德国银屑病登记 PsoBest 的结果","authors":"Lisa Schaeffer, Nesrine Ben-Anaya, Christina Sorbe, Stephan Jeff Rustenbach, Ulrich Mrowietz, Matthias Augustin","doi":"10.1080/09546634.2024.2340107","DOIUrl":null,"url":null,"abstract":"Brodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although bro...","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"50 1","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest\",\"authors\":\"Lisa Schaeffer, Nesrine Ben-Anaya, Christina Sorbe, Stephan Jeff Rustenbach, Ulrich Mrowietz, Matthias Augustin\",\"doi\":\"10.1080/09546634.2024.2340107\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Brodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although bro...\",\"PeriodicalId\":15639,\"journal\":{\"name\":\"Journal of Dermatological Treatment\",\"volume\":\"50 1\",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-04-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Dermatological Treatment\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/09546634.2024.2340107\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dermatological Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09546634.2024.2340107","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
Brodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although bro...
期刊介绍：
The Journal of Dermatological Treatment covers all aspects of the treatment of skin disease, including the use of topical and systematically administered drugs and other forms of therapy. The Journal of Dermatological Treatment is positioned to give dermatologists cutting edge information on new treatments in all areas of dermatology. It also publishes valuable clinical reviews and theoretical papers on dermatological treatments.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
